Secondary Logo

Editorial introductions

Current Opinion in Pediatrics: December 2008 - Volume 20 - Issue 6 - p ix–x
doi: 10.1097/MOP.0b013e32831cc21e
Editorial introductions
Free

Current Opinion in Pediatrics was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of pediatrics is divided into 18 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. In addition to this, Hank Bernstein also invites a prominent authority in the field of Office Pediatrics to write on the subject for each issue. Here we are pleased to introduce the Section Editors for this issue.

Back to Top | Article Outline

Section Editors

Nathaniel H. Robin

Figure 1

Figure 1

Dr Nathaniel H. Robin grew up in Hempstead, New York, USA, and attended Bowdoin College in Brunswick, Maine. After graduating in 1985, as Phi Beta Kappa and Summa Cum Laude, Dr Robin attended Albert Einstein College of Medicine in the Bronx, New York, where he remained as a resident in pediatrics through 1992. He then proceeded to the Children's Hospital Philadelphia/University of Pennsylvania as a fellow in the divisions of human genetics and molecular biology and biochemical genetics. Following his fellowship, he accepted a faculty position in the Department of Genetics at Case Western Reserve University School of Medicine in 1995. In 2003, Dr Robin joined the newly created Departments of Genetics at the University of Alabama at Birmingham.

Dr Robin's is board certified both by the American Academy of Pediatrics and the American Board of Medical Genetics. His clinical practice is primarily as a general geneticist, with expertise in pediatric genetics, syndrome identification and genetic counseling. His areas of focused interest include craniofacial disorders, and the genetics of deafness. While maintaining an active clinical practice, Dr Robin has written eight book chapters, over a dozen invited editorials and over 70 peer-review publications. His writings cover a wide range of topics in genetics and include descriptions and studies on a variety of genetic syndromes. He has published studies that have looked at genetics testing for deafness, and on ethical issues in genetic testing, including issues of confidentiality and duty to warn at risk relatives. Dr Robin is the residency program director both at The University of Alabama at Birmingham, and is currently a member of the ACGME's National Residency Review Committee for Genetics.

Back to Top | Article Outline

Scott L. Pomeroy

Figure 2

Figure 2

Scott L. Pomeroy, Chair of the Department of Neurology, Neurologist-in-Chief of Children's Hospital Boston and Bronson Crothers Professor of Neurology at Harvard Medical School, USA, graduated from Miami University in Oxford, Ohio (summa cum laude, Phi Beta Kappa) and was the first graduate of the M.D., Ph.D. program at the University of Cincinnati (Alpha Omega Alpha, Bogan Research Award, PICO award).

From 1982 to 1987, Dr Pomeroy trained in pediatrics at Children's Hospital Boston and in child neurology at Washington University in St. Louis. In 1989, he won the Child Neurology Society Young Investigator Award for work done as a postdoctoral fellow with Dale Purves at Washington University. He returned to Children's Hospital Boston in 1991, serving as neurology inpatient service chief (1994–8), chair of the neurology residency training committee (1993–7), director of the Mental Retardation Research Center imaging core (1995-present), and a member of the Neurology Executive Committee (1992-present). In 1991, he established the neuro-oncology program within the neurology department and in 1992 co-founded the Children's Hospital/Dana-Farber Pediatric Brain Tumor Clinic.

Dr Pomeroy was appointed Chairman of the Department of Neurology and Neurologist-in-Chief of Children's Hospital Boston in 2005. He has been active in the Child Neurology Society, serving on the awards committee (1989–1993), as chair of the research committee (1993–1997), and as a member of the Strategic Planning Committee (1997-present). He is Chair and Co-Chair respectively of the Tumor Biology Subcommittees of the Pediatric Brain Tumor Consortium and the Children's Oncology Group. In 1999, he co-directed a neurobiology of disease course on brain tumor biology for the Society for Neuroscience. Over the past three years, he has reviewed grants for the National Institutes of Health, Medical Research Council of Canada, the Alberta Cancer Foundation, National Cancer Institute of Canada, the Israel Science Foundation and the March of Dimes, was a session co-chair of the NCI/NINDS Brain Tumor Progress Review Group (2000), and served as a consultant to the FDA Oncologic Drugs Committee (2001). He has been chair of the Medical Advisory Board of the Brain Tumor Society since 1998. In 1999, Dr Pomeroy became the first recipient of the Kenneth B. Schwartz Center Compassionate Caregiver Award. In 2000, he received the Boston Globe/Celtics “Heroes Among Us” award and received citations from the Massachusetts Senate and House of Representatives.

Back to Top | Article Outline

Ramsay Fuleihan

Figure 3

Figure 3

Dr Ramsay Fuleihan received his medical and undergraduate degrees from the American University of Beirut, Lebanon, in 1985. He completed his residency training in pediatrics at Duke University Medical Center in Durham, North Carolina, USA, in 1988, and a fellowship in allergy and immunology at Children's Hospital in Boston Massachussetts, in 1991. He remained on faculty at the Children's Hospital until he moved to the Department of Pediatrics at Yale University School of Medicine in 1994 where he is currently the Director of the Allergy and Clinical Immunology Program. Dr Fuleihan is involved in both clinical activities and bench research. He is board certified in pediatrics and in allergy and immunology and is a member of the American Academy of Allergy, Asthma and Immunology, the American Association of Immunologists, the Clinical Immunology Society and the Pan American Group for Immune Deficiency, and the Society for Pediatric Research. His clinical practice is in both allergic diseases and primary immunodeficiency diseases and he is Director of the Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies at Yale University School of Medicine. Dr Fuleihan's research is focused on the pathogenesis and therapy of primary immunodeficiency diseases as well as the transcriptional regulation of lymphocyte development.

Back to Top | Article Outline

Michael Cabana

Figure 4

Figure 4

Michael Cabana, MD, MPH, Professor of Pediatrics, Epidemiology and Biostatistics, is the Director of the Division of General Pediatrics at the University of California, San Francisco (UCSF), USA. He is a member of the core faculty at the Philip Lee Institute for Health Policy Studies at UCSF and Director of the General Pediatrics Fellowship Program at UCSF.

Dr Cabana's research interests include understanding variation in physician practice as it relates to quality of care, particularly in asthma. His work has focused on measurement of quality of care, physician use of clinical practice guidelines and primary prevention of asthma.

Dr Cabana completed his undergraduate medical training through the combined program at the University of Pennsylvania School of Medicine and the Wharton School of Business, where he earned a masters degree in public policy and management. Dr Cabana trained in pediatrics at the Harriet Lane Service at the Johns Hopkins Children's Center. He continued at Johns Hopkins as a Robert Wood Johnson Clinical Scholar, where he completed his masters in public health at the same institution.

Dr Cabana is currently the principal investigator for the Enhancing Pediatric Asthma Management Study (R-01 HL70771), a five-year study focused at improving physician management of pediatric asthma. He is also the principal investigator for the trial of Infant Probiotic Supplementation (R-01 HL80074), a five-year randomized controlled trial to evaluate the effectiveness of probiotic supplementation in the prevention of early markers of asthma.

© 2008 Lippincott Williams & Wilkins, Inc.